Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
- 543 Downloads
Purpose. To evaluate the concordance between HER2 gene amplification, determined by fluorescence in situ hybridization (FISH), and HER2 protein overexpression assessed by an immunohistochemical (IHC) assay. The IHC protocol used was a research assay, known as the Clinical Trial Assay (CTA), developed to select women with metastatic breast cancer (MBC) for three pivotal clinical trials of trastuzumab therapy.
Methods. A direct-labeled, dual-probe FISH assay was used to determine HER2 amplification in 623 fixed breast cancer tissue specimens. These specimens had been stored as paraffin-embedded sections for 2ᾢ5 years. All specimens had been analyzed for HER2 protein expression by the CTA. To assess the reproducibility of FISH results in archived material, we evaluated a separate group of 617 breast cancer tissue specimens at two di erent laboratories.
Results. Informative FISH results were available for 529 (85%) of the 623 specimens. Overall concordance between FISH and IHC results was 82% (95% CI; 78ᾢ85%). Assay agreement between FISH results and specimens with immunostaining scores of 0, 1+, and 3+ were 97, 93 and 89%, respectively. However, only 24% of specimens with 2+ immunostaining scores had HER2 amplification by FISH; there was assay disagreement in 76% of specimens in this IHC subgroup. Interlaboratory FISH concordance was 92% (95% CI; 89ᾢ94%), indicating very good assay reproducibility in these archived specimens.
Conclusion. HER2 status determined by CTA-IHC and FISH are significantly correlated; however, differences between these two assays can a ect patient selection for trastuzumab therapy.
Keywordsfluorescence in situ hybridization (FISH) HER2 immunohistochemistry (IHC) metastatic breast cancer (MBC) trastuzumab
Unable to display preview. Download preview PDF.
- Coussens, L, Yang-Feng, TL, Liao, YC, Chen, E, Gray, A, McGrath, J, Seeburg, PH, Libermann, TA, Schlessinger, J, Francke, U, et al. 1985Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogeneScience23011321139Google Scholar
- Slamon, DJ, Clark, GM, Wong, SG, Levin, WJ, Ullrich, A, McGuire, WL 1987Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience235177182Google Scholar
- Pauletti, G, Dandekar, S, Rong, H 1998A large-scale FISH study of HER-2/neu gene amplification in breast cancer.Proc Am Assoc Cancer Res 39345(Abstract 2352)Google Scholar
- Slamon, DJ, Godolphin, W, Jones, LA, Holt, JA, Wong, SG, Keith, DE, Levin, WJ, Stuart, SG, Udove, J, Ullrich, A, et al. 1989Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience244707712Google Scholar
- Gusterson, BA, Gelber, RD, Goldhirsch, A, Price, KN, Save-Soderborgh, J, Anbazhagan, R, Styles, J, Rudenstam, CM, Golouh, R, Reed, R, et al. 1992Prognostic importance of c-erbB-2 expression in breast cancer.International (Ludwig) Breast Cancer Study GroupJ Clin Oncol1010491056Google Scholar
- Andrulis, IL, Bull, SB, Blackstein, ME, Sutherland, D, Mak, C, Sidlofsky, S, Pritzker, KP, Hartwick, RW, Hanna, W, Lickley, L, Wilkinson, R, Qizilbash, A, Ambus, U, Lipa, M, Weizel, H, Katz, A, Baida, M, Mariz, S, Stoik, G, Dacamara, P, Strongitharm, D, Geddie, W, McCready, D 1998neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer.Toronto Breast Cancer Study GroupJ Clin Oncol1613401349PubMedGoogle Scholar
- Press, MF, Pike, MC, Chazin, VR, Hung, G, Udove, JA, Markowicz, M, Danyluk, J, Godolphin, W, Sliwkowski, M, Akita, R, et al. 1993Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent diseaseCancer Res5349604970PubMedGoogle Scholar
- Press, MF, Bernstein, L, Thomas, PA, Meisner, LF, Zhou, JY, Ma, Y, Hung, G, Robinson, RA, Harris, C, El-Naggar, A, Slamon, DJ, Phillips, RN, Ross, JS, Wolman, SR, Flom, KJ 1997HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomasJ Clin Oncol1528942904PubMedGoogle Scholar
- Cobleigh, MA, Vogel, CL, Tripathy, D, Robert, NJ, Scholl, S, Fehrenbacher, L, Wolter, JM, Paton, V, Shak, S, Lieberman, G, Slamon, DJ 1999Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol1726392648PubMedGoogle Scholar
- Slamon, DJ, Leyland-Jones, B, Shak, S, Fuchs, H, Paton, V, Bajamonde, A, Fleming, T, Eiermann, W, Wolter, J, Pegram, M, Baselga, J, Norton, L 2001Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med344783792CrossRefPubMedGoogle Scholar
- Vogel, CL, Cobleigh, MA, Tripathy, D, Gutheil, JC, Harris, LN, Fehrenbacher, L, Slamon, DJ, Murphy, M, Novotny, WF, Burchmore, M, Shak, S, Stewart, SJ, Press, M 2002Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol20719726CrossRefPubMedGoogle Scholar
- Pauletti, G, Dandekar, S, Rong, H, Ramos, L, Peng, H, Seshadri, R, Slamon, DJ 2000Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistryJ Clin Oncol1836513664PubMedGoogle Scholar
- Thomson, TA, Hayes, MM, Spinelli, JJ, Hilland, E, Sawrenko, C, Phillips, D, Dupuis, B, Parker, RL 2001HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridizationMod Pathol1410791086CrossRefPubMedGoogle Scholar
- Seidman , AD, Fornier, MN, Esteva, FJ, Tan, L, Kaptain, S, Bach, A, Panageas, KS, Arroyo, C, Valero, V, Currie, V, Gilewski, T, Theodoulou, M, Moynahan, ME, Moasser, M, Sklarin, N, Dickler, M, D‘Andrea, G, Cristofanilli, M, Rivera, E, Hortobagyi, GN, Norton, L, Hudis, CA 2001Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationJ Clin Oncol1925872595PubMedGoogle Scholar
- Tsuda, H, Akiyama, F, Terasaki, H, Hasegawa, T, Kurosumi, M, Shimadzu, M, Yamamori, S, Sakamoto, G 2001Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinomaInterobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer9229652974Google Scholar
- Birner, P, Oberhuber, G, Stani, J, Reithofer, C, Samonigg, H, Hausmaninger, H, Kubista, E, Kwasny, W, Kandioler-Eckersberger, D, Gnant, M, Jakesz, R 2001Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancerClin Cancer Res716691675PubMedGoogle Scholar
- Fleiss, J 1981Statistical Methods of Rates and Proportions2John Wiley & Sons, IncNew York217Google Scholar
- Mass RD, Press MF, Anderson S: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer, 2005 (in press).Google Scholar
- Battifora, H, Kopinski, M 1986The influence of protease digestion and duration of fixation on the immunostaining of keratinsA comparison of formalin and ethanol fixation. J Histochem Cytochem3410951100Google Scholar
- Press MF SG, Bernstein L, Mirlacher M, Villalobos I, Zhou J, Riva A, Nabholtz JM, Slamon DJ: Diagnostic evaluation of HER-2/neu as a molecular therapeutic target: local testing versus centralized FISH testing. Lab Invest 83: 43a, 2003Google Scholar
- Vincent-Salomon, A, Jouve, M, Genin, P, Freneaux, P, Sigal-Zafrani, B, Caly, M, Beuzeboc, P, Pouillart, P, Sastre-Garau, X 2002HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processCancer9421692173CrossRefPubMedGoogle Scholar
- Simon, R, Nocito, A, Hubscher, T, Bucher, C, Torhorst, J, Schraml, P, Bubendorf, L, Mihatsch, MM, Moch, H, Wilber, K, Schotzau, A, Kononen, J, Sauter, G 2001Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancerJ Natl Cancer Inst9311411146Google Scholar
- Paik, S, Tan-Chiu, E, Bryant, J, Romond, E, Brown, A, Mull, J, Hiller, W, Finnigan, M, Wolmark, N 2002Successful quality assurance program for HER2 testing in the NSABP trial for HerceptinBreast Cancer Res Treat 76S31Google Scholar
- CAP, 2002Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testingArch Pathology Lab Med126803808Google Scholar
- Diest , PJ vDP, Henzen-Logmans, SC, Berns, E, Burg, ME, Green, J, Vergote, I 1997A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative GroupJ Clin Pathol50801804PubMedGoogle Scholar
- Going, JJ, Mallon, L, Reeves, JR, Watters, AD, Richmond, J, Donald, B, Ferrier, R, Cooke, T, Bartlett, J 2000Inter-observer agreement in assessing C-ERBB-2 status in breast cancer: immunhistochemistry and FISH.J Pathol 19019AGoogle Scholar